Answers are grounded in this paper and cite their sources.
A paradigm shift, championed largely by cellular immunologists, has redefined asthma as an immune mediated phenomenon characterised by an interleukin 5 (IL-5) driven eosinophilic bronchitis. This change in emphasis has provoked intense interest in the possibility that inhibitors of IL-5 production, or antagonists of its activity, will provide a new generation of anti-asthma drugs.
No takes yet. Share an insight, caveat, or question.
Singh et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: